Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

While immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the clinical management of various malignancies, a large fraction patients are refractory to ICIs employed as standalone therapeutics, necessitating development combinatorial treatment strategies. Immunogenic cell death (ICD) inducers have attracted considerable interest partners for ICIs, at least in part owing their ability initiate tumor-targeting adaptive response. However, compared either approach alone, regimens involving ICD and not always shown superior activity. Here, we discuss accumulating evidence on therapeutic interactions between oncological settings, identify key factors that may explain discrepancies preclinical findings, propose strategies address existing challenges increase efficacy these combinations cancer.

Language: Английский

---

Next-generation combination approaches for immune checkpoint therapy

Nature Immunology, Journal Year: 2024, Volume and Issue: 25(12), P. 2186 - 2199

Published: Nov. 25, 2024

Language: Английский

---

Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 196, P. 104321 - 104321

Published: March 7, 2024

Language: Английский

---

Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6750 - 6750

Published: June 19, 2024

The management of advanced bladder carcinoma involves a multidisciplinary approach, but the prognosis remains poor for many patients. immune system plays crucial role in this disease, influencing both tumor development and response to treatment, exploiting against can be valuable strategy destroy neoplastic cells. This is biological principle underlying Bacillus Calmette-Guérin (BCG) use and, more recently, checkpoint inhibitors (ICIs), like PD-1 (programmed death-1)/PD-L1 death-ligand 1) inhibitors. In fact, one best studied checkpoints represented by PD-1/PD-L1 axis, which well-known escape adopted PD-L1 expression has been associated with higher pathologic stage shown prognostic value carcinoma. Interestingly, high-grade cancers tend express levels PD-L1, suggesting potential such an axis mediating disease progression. Immunotherapy therefore emerged as treatment option efficacy cancer patients, high better responses. Our review aims provide comprehensive overview cancer, focusing on its implications decisions prediction response. Overall, our work contribute understanding predictive biomarker highlight shaping therapeutic approaches cancer.

Language: Английский

---

Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: 16(35), P. 45901 - 45916

Published: Aug. 22, 2024

Immune checkpoint blockade (ICB) therapy, while showing promise in various cancers, exhibits limited effectiveness hepatic carcinoma due to the tumor's immunosuppressive microenvironment (TME) and challenges associated with immune cell infiltration. Efforts transform "cold" TME into an "inflamed" state, notably through chemo-immunotherapy, have sparked interest their potential induce immunogenic death augment infiltration of cytotoxic T lymphocytes (CTLs). Nonetheless, efficacy chemo-immunotherapy is often compromised by suboptimal pharmacokinetics, poor tumor accumulation, off-target toxicity. Herein, response, we introduce innovative, milder thermal therapeutic approach leveraging gold nano frameworks mesopores for targeted delivery immunostimulant imiquimod NIR-II photothermal therapy. This strategy employs molecule modifications ensure precise targeting, guided photoacoustic imaging. Subsequent mild treatment, there a release proteins (CRT HSP90), enhancing immunogenicity. Assisted imiquimod, substantial CTL occurs, accompanied pro-inflammatory factor (TNF-α, IL-6), transforming M2 macrophages M1 phenotype. Ultimately, proposed combines PD-L1/PD-1 blockade, treatment synergistically enhance immunogenicity, remodel TME, restrain carcinoma, making strides ICB synergistic immune-thermal

Language: Английский

---

Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 509 - 509

Published: Feb. 3, 2025

Background: For many decades, gemcitabine + cisplatin has been a preferred and accepted treatment option for patients with urothelial cancer (UC). In ineligible standard-dose cisplatin, split-dose is promising alternative. This study aimed to provide insights into the use of factors influencing choice. Methods: Between January March 2024, an international cross-sectional survey was carried out, which involved oncologists urologists treating locally advanced/metastatic UC (la/mUC) in Australia, Brazil, Canada, France, Germany, India, Italy, Spain, UK, USA. Demographics, practice patterns, clinical parameters choice were collected. Results: Of 791 respondents, most male (73%), mean age 43 years, time spent 13 years. total, 85% reported using UC, ranging from 97% Canada 67% Brazil. The schedule la/mUC 35 mg/m2 on days 1 8 21-day cycles (57%). Most respondents (64%) comfortable prescribing otherwise fit creatinine clearance ≥40 mL/min. Standard- regimens 45–60 Conclusions: large demonstrates extensive la/mUC. Responses indicate that administered wider range clearance, performance status, comorbidities than suggested cisplatin. Results highlight need evaluate prospectively establish consensus guidelines its use, especially unfit

Language: Английский

---

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 134, P. 102900 - 102900

Published: Feb. 10, 2025

The treatment landscape for patients with advanced urothelial carcinoma (UC) has evolved rapidly in recent years. In current guidelines, combination enfortumab vedotin plus pembrolizumab is the first-line (1L) standard of care, and other recommended 1L options are platinum-based chemotherapy followed by avelumab as switch-maintenance without progression, or nivolumab, cisplatin, gemcitabine cisplatin-eligible only. Individual differ terms their health status, disease characteristics, expected toxicities, preferences; thus, a "one-size-fits-all" approach to unlikely be optimal. availability several creates potential individualized treatment. this review, we discuss factors that may considered when selecting UC, including efficacy safety data from phase 3 trials real-world studies, quality life, patient priorities treatment, sequencing, biomarkers, access cost. Patients physicians should benefit-risk balance all available enable shared decision-making. Longer follow-up clinical additional studies needed further inform selection.

Language: Английский

---

Phenotypic characterization of tumor associated macrophages and circulating monocytes in patients with Urothelial carcinoma of bladder

Immunologic Research, Journal Year: 2025, Volume and Issue: 73(1)

Published: April 7, 2025

Language: Английский

---

Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 9, 2025

There is still controversy regarding the safety and efficacy of atezolizumab for treatment urothelial carcinoma (UC). This research aimed to extensively investigate effectiveness as a therapy UC. A thorough literature review was conducted using databases including PubMed, Embase, Cochrane Library, Web Science. The search included studies published from inception each database until May 24, 2024. primary outcomes, progression-free survival (PFS) overall (OS), were calculated hazard ratios (HRs) their corresponding 95% confidence intervals (CIs). Ten randomized controlled trials (RCTs) totaling 4,148 participants in our analysis. Compared UC patients who received placebo, either alone or combination with chemotherapy medications, aggregated data showed that had significantly longer OS(HR = 0.88, CI [0.83, 0.94], p < 0.0001). Three RCTs also provided on PFS, showing atezolizumab, addition instead chemotherapy, PFS than those placebo without (HR 0.85, [0.76, 0.95], 0.004). Atezolizumab has demonstrated significant improvements OS among UC, offering crucial insights decision-making immunotherapy. https://www.crd.york.ac.uk/PROSPERO/#recordDetails , identifier [CRD42024556757].

Language: Английский

---

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(9), P. 1311 - 1325

Published: June 18, 2024

Language: Английский

---